BioMarin Pharmaceuticals BMRN Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's total liabilities?
- BioMarin Pharmaceuticals (BMRN) reported total liabilities of $2.38B in Q1 2026.
- How has BioMarin Pharmaceuticals's total liabilities changed year-over-year?
- BioMarin Pharmaceuticals's total liabilities increased by 75.8% year-over-year, from $1.35B to $2.38B.
- What is the long-term trend for BioMarin Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's total liabilities has grown at a -2.9% compound annual growth rate (CAGR), from $1.74B to $1.51B.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors.
- How do you interpret total liabilities?
- Rising total liabilities relative to equity may indicate increasing financial leverage and risk, requiring careful monitoring of debt service capacity.
- How does total liabilities compare across companies?
- Standard metric for assessing total financial burden; compared against equity to determine solvency.